Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P46059

UPID:
S15A1_HUMAN

ALTERNATIVE NAMES:
Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; Peptide transporter 1

ALTERNATIVE UPACC:
P46059; Q5VW82

BACKGROUND:
The protein Solute carrier family 15 member 1, known alternatively as Intestinal H(+)/peptide cotransporter or Peptide transporter 1, is pivotal in the absorption of dietary peptides. It efficiently transports oligopeptides of 2 to 4 amino acids, with a preference for dipeptides, across the small intestine's epithelial barrier. This process is essential for the optimal absorption of nutrients. Furthermore, its role in the transport of muramyl and N-formylated bacterial dipeptides contributes significantly to the immune system's ability to detect and respond to microbial pathogens.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Solute carrier family 15 member 1 offers promising avenues for the development of novel therapeutic interventions aimed at improving gastrointestinal health and immune response.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.